Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Total Current Liabilities: 2012-2024

Historic Total Current Liabilities for Agios Pharmaceuticals (AGIO) over the last 13 years, with Dec 2024 value amounting to $81.2 million.

  • Agios Pharmaceuticals' Total Current Liabilities fell 37.42% to $74.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.8 million, marking a year-over-year decrease of 37.42%. This contributed to the annual value of $81.2 million for FY2024, which is 19.43% up from last year.
  • According to the latest figures from FY2024, Agios Pharmaceuticals' Total Current Liabilities is $81.2 million, which was up 19.43% from $68.0 million recorded in FY2023.
  • In the past 5 years, Agios Pharmaceuticals' Total Current Liabilities registered a high of $94.4 million during FY2020, and its lowest value of $59.8 million during FY2021.
  • Moreover, its 3-year median value for Total Current Liabilities was $68.0 million (2023), whereas its average is $70.6 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first plummeted by 36.62% in 2021, then rose by 19.43% in 2024.
  • Over the past 5 years, Agios Pharmaceuticals' Total Current Liabilities (Yearly) stood at $94.4 million in 2020, then tumbled by 36.62% to $59.8 million in 2021, then rose by 4.69% to $62.6 million in 2022, then rose by 8.50% to $68.0 million in 2023, then increased by 19.43% to $81.2 million in 2024.